As Chief Financial Officer & Head of Corporate Development, George. O Elston leads EyePoint Pharmaceuticals’ financial, capital markets, and corporate development initiatives. Mr. Elston has leveraged his more than 30 years of diverse financial and senior leadership in the biopharmaceutical sector to propel the Company’s strategic, operational, and business goals forward. Prior to joining EyePoint in 2019, Mr. Elston served as Chief Financial Officer & Head of Corporate Development at Enzyvant Therapeutics, where he helped build the precommercial rare disease firm, leading to its eventual acquisition. He previously served as President and Chief Executive Officer at 2X Oncology, Inc., where he advanced the company from a spin-out into a multiprogram, clinical-stage organization, and held senior executive roles at Juniper Pharmaceuticals, Inc.; KBI Biopharma; and Optherion, Inc. Mr. Elston began his career in public accounting at PriceWaterhouseCoopers. He holds a B.B.A in Accounting from Pace University and is a Certified Public Accountant. Mr. Elston currently serves as a Board Member of the DWS – DBX ETF Trust.
Menu